Loading...
01/11 16:20
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. While there are positive developments, such as the acquisition of Lavie Bio by ICL and reduced expenses, there are concerns over declining revenues, operational risks, and funding challenges. The Q&A session highlights management's reluctance to provide clear guidance, raising uncertainties. Despite reduced expenses and a cash inflow from asset sales, the reliance on subsidiaries for revenue and the lack of clarity on future orders temper optimism. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
Total Revenues $2.4 million (decrease of approximately 43% year-over-year from $4.2 million); decrease primarily due to $3.5 million in license fee payments recognized in Q1 2024 from Lavie Bio and AgPlenus.
Total R&D Expenses $3.2 million (decrease of approximately 33% year-over-year from $4.8 million); decrease mainly due to reduced R&D activity in Biomica and Lavie Bio, and closure of Canonic's operations.
Total Sales and Marketing Expenses $0.6 million (decrease of approximately 35% year-over-year from $1 million); decrease primarily due to reduced sales and marketing activity in Lavie Bio.
Total Operating Expenses Net $5 million (decrease of approximately 38% year-over-year from $8 million); decrease mainly due to reduced operating activity in Lavie Bio and Biomica.
Cash and Short-term Bank Deposits $9.8 million (decrease from $15.3 million as of December 31, 2024); cash balance does not reflect $2 million due from Casterra's outstanding customers.
Net Loss $3 million (decrease of approximately 21% year-over-year from $3.8 million); decrease primarily due to reduced operating expenses and increased net financing income.
Net Financing Income $1.5 million (compared to net financing income of approximately $241,000 in the same period last year); increase due to accounting treatment of pre-funded warrants and warrants issued in August 2024.
ChemPass-AI for pharma: Refined value proposition for pharmaceutical and biotech sectors, focusing on designing novel compounds.
BMC128: Phase I clinical study shows early signs of effectiveness through immune activation.
New mode of action for fungicides: AgPlenus discovered a new mode of action for fungicides against Septoria in wheat.
Casterra seed sales: Casterra delivered 250 tons of castor seeds to Africa, surpassing 2024's total.
Lavie Bio acquisition: ICL to acquire Lavie Bio's activities for $15.25 million, expected to close in Q2 2025.
MicroBoost AI sale: ICL to acquire MicroBoost AI tech-engine for approximately $3.5 million.
Expense reduction plan: Evogene established an expense reduction plan expected to be completed by Q2 2025.
R&D expenses: R&D expenses decreased to $3.2 million from $4.8 million year-over-year.
Sales and marketing expenses: Sales and marketing expenses decreased to $0.6 million from $1 million year-over-year.
Focus on ChemPass-AI: Evogene aims to enhance ChemPass-AI for drug discovery and develop a capital-efficient model.
Exit events for subsidiaries: Evogene is focusing on creating exit events for subsidiaries to generate value and cash.
Geopolitical Risks: The ongoing war between Israel, Hamas, and Hezbollah poses significant risks to Evogene's operations, particularly if the situation escalates further.
Regulatory Risks: The acquisition of Lavie Bio by ICL is subject to customary and regulatory closing conditions, which may introduce delays or complications.
Financial Risks: Evogene's cash balance has decreased from approximately $15.3 million to $9.8 million, indicating potential liquidity challenges. Additionally, the company reported a significant decline in revenues from $4.2 million to $2.4 million, primarily due to the absence of prior license fee payments.
Operational Risks: The closure of Canonic's operations has resulted in additional expenses and may impact overall operational efficiency.
Funding Risks: Biomica requires additional funding to advance to Phase II of its clinical study for BMC128, which may pose challenges in securing necessary financial resources.
Market Risks: Evogene's revenue generation is heavily reliant on its subsidiaries, and any underperformance in these areas could adversely affect overall financial health.
Expense Reduction Plan: Evogene established an expense reduction plan, which will be completed by the second quarter of 2025, already partially reflected in Q1 2025 results.
Acquisition of Lavie Bio by ICL: Evogene announced the acquisition of most of Lavie Bio's activities by ICL for an aggregate value of $15.25 million, expected to close in Q2 2025.
Casterra Seed Sales: Casterra delivered 250 tons of castor seeds to its partner in Africa, surpassing the total of 215 tons delivered in 2024.
AgPlenus Discovery: AgPlenus announced the discovery of a new mode of action for fungicides against Septoria in wheat, with plans to engage potential licensing partners by year-end.
Biomica Phase I Study: Biomica's Phase I clinical study of BMC128 is progressing, with early signs of effectiveness observed within 14 days of treatment.
Revenue Expectations: Total revenues for Q1 2025 were approximately $2.4 million, down from $4.2 million in Q1 2024, primarily due to a lack of license fee payments.
Future Cash Flow: Expected proceeds from the sale of Lavie Bio’s assets and MicroBoost AI tech-engine to ICL, anticipated to close in Q2 2025.
Funding for Biomica: Additional funding is necessary for Biomica to advance to Phase II of the clinical study for BMC128.
Sales Strategy for Casterra: Casterra has initiated proof-of-concept trials for grain cultivation in Kenya and Brazil, with expected initial results in Q3 2025.
Acquisition of Lavie Bio by ICL: On April 21, 2025, Evogene announced the acquisition of most of Lavie Bio’s activity and assets by ICL for an aggregate value of $15.25 million. Additionally, ICL will acquire Evogene’s MicroBoost AI tech-engine for approximately $3.5 million. This transaction is expected to generate value for Evogene through direct sales and potential future dividends as Evogene remains a major shareholder in Lavie Bio.
The earnings call reveals a mixed but overall positive sentiment. Financial performance shows improvement in net loss and operating loss, though revenues slightly decreased. The AI ChemPass platform is gaining interest, with potential partnerships on the horizon. Management's enthusiasm for AI ChemPass and planned IR activities could boost investor confidence. Despite some unclear responses in the Q&A, the focus on strategic partnerships and financial health supports a positive outlook for stock price movement.
The earnings call highlights strong revenue growth, significant reductions in operating expenses, and promising developments in castor seed sales and field trials. The Q&A section reveals optimism about future collaborations and advancements, particularly in the ChemPass AI platform. Despite some vague responses, the focus on new strategies and partnerships suggests a positive outlook. The financial improvements and strategic plans indicate a likely stock price increase of 2% to 8% over the next two weeks.
The earnings call presents a mixed picture. While there are positive developments, such as the acquisition of Lavie Bio by ICL and reduced expenses, there are concerns over declining revenues, operational risks, and funding challenges. The Q&A session highlights management's reluctance to provide clear guidance, raising uncertainties. Despite reduced expenses and a cash inflow from asset sales, the reliance on subsidiaries for revenue and the lack of clarity on future orders temper optimism. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
The earnings call reveals several concerning factors: a significant decline in revenue, a reduced cash position, and geopolitical risks. Despite some positive developments like the acquisition of Lavie Bio and reduced expenses, the dependency on collaborations and the absence of license fee payments pose substantial risks. Additionally, the financial sustainability is questionable due to decreased cash reserves and reliance on future funding. The analysts' sentiment is unclear, but the overall financial picture and risks suggest a negative market reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
